Protagonist Therapeutics, Inc.
PTGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.37 | 0.88 | -0.34 |
| FCF Yield | 7.69% | -5.44% | -20.36% | -6.88% |
| EV / EBITDA | 9.06 | -12.35 | -3.14 | -11.92 |
| Quality | ||||
| ROIC | 35.69% | -27.72% | -57.39% | -39.90% |
| Gross Margin | 100.00% | 100.00% | 96.12% | 89.86% |
| Cash Conversion Ratio | 0.67 | 0.89 | 0.85 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 153.78% | 29.93% | -2.44% | 391.08% |
| Free Cash Flow Growth | 358.02% | 34.96% | 0.03% | -49.36% |
| Safety | ||||
| Net Debt / EBITDA | -0.34 | 2.05 | 0.93 | 0.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -10.98 | 0.33 |
| Cash Conversion Cycle | 141.56 | 62.85 | -1,319.94 | 979.12 |